Cancer Research UK scientists at The University of Manchester found that some melanoma cells are particularly fast growing, but not very good at invading the surrounding tissue, while other melanoma cells are the opposite — highly invasive but slow-growing. …
According to senior author John L. VandeBerg, Ph.D., the research was driven by the fact that, despite the increasing use of sunscreen in recent decades, the incidence of malignant melanoma, the most aggressive form of skin cancer, continues to increase dramatically. The American Cancer Society estimates that more than 75,000 new cases of melanoma will be diagnosed in the U.S. this year. …
“Patients with metastatic pancreatic cancer or pancreatic cancer in general have very limited options,” said study author Andrea Wang-Gillam, assistant professor in the Division of Oncology at Washington University in St. Louis, USA. “These patients just simply don’t do well. …
“These results reinforce the need for care providers to better understand and communicate with patients about the possible long-term effects of bilateral RRSO,” said lead author Susan Domchek, MD, director of Penn’s Basser Research Center for BRCA. …
“As soon as somebody hears they have a 65 percent chance of a new breast cancer in the future or an up to 60 percent chance of ovarian cancer, they are likely to do whatever they can to prevent that,” said lead author Dr. …
The new type of magnetic resonance imaging (MRI) scan could improve care for a type of cancer called myeloma and reduce reliance on bone marrow biopsies, which can be painful for patients and often fail to show doctors how far the disease has spread. The research is published today in the journal Radiology and was carried out by researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust. It received funding from Cancer Research UK and the National Institute for Health Research Clinical Research Facility in Imaging, with additional funding from the EPSRC. The new whole-body, diffusion-weighted MRI scans showed the spread of cancer throughout the bone marrow of patients with myeloma — one of the most common forms of blood cancer — more accurately than standard tests…
This research focused on the immune system’s dendritic cells (DCs), crucial cells that initiate and regulate immune responses. For example, the dendritic cells activate T lymphocytes to fight an infection or cancer. Curiously, they are also known to suppress the immune response. Determining when DCs turn the immune response “on” or “off” is a major question in immunology. …
The international team from CIC bioGUNE, the University of Liverpool and the US research centre USC-UCLA has successfully unravelled the mechanism by which two proteins, MATα2 and MATβ, bind to each other, thereby promoting the reproduction of tumour cells in liver and colon cancers. The study was announced in the latest issue of the open access journal IUCrJ published by the IUCr. This structural data discovery opens up additional research opportunities into drugs that can act on the binding of these proteins, thereby possibly inhibiting cancer cell growth. …
ACP’s new evidence-based clinical practice guideline, “Screening Pelvic Examination in Adult Women,” was published today in Annals of Internal Medicine, ACP’s flagship journal. ACP’s guideline is based on a systematic review of the published literature on human subjects in the English language from 1946 through January 2014. “Routine pelvic examination has not been shown to benefit asymptomatic, average risk, non-pregnant women. It rarely detects important disease and does not reduce mortality and is associated with discomfort for many women, false positive and negative examinations, and extra cost,” said Dr. …
In a comparison of the three strategies, Julia C. Gage, Ph.D., M.P.H., of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, and colleagues analyzed data from the Kaiser Permanente Northern California (KPNC) large integrated health delivery system, which screened women age 30-64 since 2003 with both HPV and Pap testing. Data were available through 2012, and over 1 million women were screened at approximately 3-year intervals, with a mean follow-up time of 4.36 years. For each testing strategy, they estimated the cumulative risk of cervical cancer after a negative test result. …